Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123662) titled '?d T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangzhou Bio-gene Technology Co., Ltd
Condition:
Leukemia
Myeloid
Acute
Intervention:
Biological: Gamma-Delta T cell injection
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: September 1, 2025
Target Sample Size: 8
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07123662
Published by HT Digital C...